Basiliximab Approval Info - Licensing Action

Proper name: Basiliximab
Tradename: Simulect
Manufacturer: Novartis Pharmaceutical Corp, East Hanover, NJ, License #1244
Indication for Use: Use in renal transplantation in combination with triple immunosuppressive therapy; use in pediatric renal transplantation; and use of an IV bolus injection
Approval Date: 3/23/2001
Type of submission: Biologics license application supplement


Approval Letter (PDF)

Label (PDF)

Page Last Updated: 04/06/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English